Allergies are widely considered to be misdirected type 2 immune responses, in which immunoglobulin E (IgE) antibodies are produced against any of a broad range of seemingly harmless antigens. However, components of insect venoms also can sensitize individuals to develop severe IgE-associated allergic reactions, including fatal anaphylaxis, upon subsequent venom exposure. We found that mice injected with amounts of honeybee venom similar to that which could be delivered in one or two stings developed a specific type 2 immune response that increased their resistance to subsequent challenge with potentially lethal amounts of the venom. Our data indicate that IgE antibodies and the high affinity IgE receptor, FcεRI, were essential for such acquired resistance to honeybee venom. The evidence that IgE-dependent immune responses against venom can enhance survival in mice supports the hypothesis that IgE, which also contributes to allergic disorders, has an important function in protection of the host against noxious substances.
INTRODUCTION
Allergies, which afflict 20%-30% of people worldwide, are detrimental immune responses against any of a large variety of environmental antigens (Pawankar et al., 2012) . Such antigens (called allergens) share the ability to elicit acquired type 2 immune responses, which are orchestrated by CD4 + T helper type 2 (Th2) cells and include the production of allergen-specific immunoglobulin E (IgE) antibodies (Galli and Tsai, 2012; Paul and Zhu, 2010; Pulendran and Artis, 2012) . During infections with helminthes and certain other parasites, IgE-associated Th2 cellmediated responses are thought to contribute to host defense (Finkelman et al., 2004; Fitzsimmons and Dunne, 2009; Pulendran and Artis, 2012; Stetson et al., 2004) . However, when IgEassociated immune responses are directed against other types of allergens, such as those in foods or medicines, allergen exposure of certain sensitized individuals can induce anaphylaxis, an acute, catastrophic, and potentially fatal systemic reaction (Finkelman, 2007; Portier and Richet, 1902) . Because most allergens do not represent a threat to the nonsensitized host, Th2 cell responses resulting in antigen-specific IgE antibodies to such allergens are widely considered to be misdirected and maladaptive immune responses Holgate and Polosa, 2008) . In 1991, Margie Profet suggested that the common feature of most allergens is their origin from sources (such as nuts, seafood, or venoms), which either might (e.g., foods) or always (e.g., venoms) contain toxins (Profet, 1991) . Profet also proposed that allergic reactions (manifested as immediately occurring symptoms, such as coughing or diarrhea) evolved as a defense mechanism that allows the sensitized host to respond immediately to, and to neutralize and/or avoid, noxious substances that might be indicative of potentially life-threatening situations (Profet, 1991) . However, until recently (Palm et al., 2012 ), Profet's ''toxin hypothesis'' was largely ignored by the scientific community and, to date, supporting experimental evidence has been missing.
In mammals, venoms provoke an innate inflammatory response and pathology related to the biological activities of the toxic components (Habermann, 1972; Mukherje et al., 2000; Risch et al., 2009) . Venoms also can induce allergic sensitization and development of specific IgE antibodies (Annila, 2000; Charavejasarn et al., 1975; Jarisch et al., 1979; Saelinger and Higginbotham, 1974; Wadee and Rabson, 1987) , which bind to the high affinity IgE receptor, FcεRI, on tissue mast cells (MCs) and blood basophils, priming them to release mediators of allergy and anaphylaxis upon subsequent venom exposure (Charavejasarn et al., 1975; Finkelman, 2007; Galli and Tsai, 2012; Oettgen and Geha, 1999; Saelinger and Higginbotham, 1974) . MCs also can be activated directly by certain venoms, in the absence of specific IgE, and work in mice indicates that innate functions of MCs, including degradation of venom toxins by MC-derived proteases, can enhance host resistance to the venoms of certain arthropods (including the honeybee) and reptiles (Akahoshi et al., 2011; Metz et al., 2006; Schneider et al., 2007) . However, it is not known whether acquired type 2 immunity against venoms also can enhance host defense.
We found that a type 2 immune response and associated IgE antibodies against honeybee venom were able to increase host resistance to challenge with a potentially lethal dose of venom, an effect that was mediated by FcεRI. Our data indicate that one function of IgE, which is best known for its role in allergic reactions, is to protect the host against noxious substances.
RESULTS
Mice Develop an Antigen-Specific Th2 Cell Response after Immunization with Honeybee Venom Honeybee (Apis mellifera) venom (BV) consists of a mixture of cytolytic peptides (e.g., melittin), enzymes (e.g., phospholipase A 2 [PLA 2 ; considered the main allergen in BV]), hyaluronidase, neurotoxins, and bioactive amines (Habermann, 1972) and accounts for the majority of venom allergies in humans (Biló et al., 2005) . To assess their susceptibility to BV, we injected naive wild-type (WT) Th1 cell response-prone C57BL/6 mice and Th2 cell response-prone BALB/c mice subcutaneously (s.c.) with increasing total amounts of complete, unprocessed BV at one to five different sites. Each injection contained 100 to 200 mg of BV, mimicking the amount of venom typically found in individual honeybees (our immunization dosages therefore correspond to $1 to 5-10 honeybee stings; Metz et al., 2006; Schmidt, 1995) (Figures 1A to 1C) . Acute reactions to BV were characterized by dose-dependent reductions in both body temperature ( Figures 1D and 1F ) and survival (Figures 1E and 1G) . Similar results were obtained with Russell's viper venom, which also induced dose-dependent toxicity (see Figures S1A to S1G available online).
Honeybee stings can induce a Th2 cell-mediated immune response associated with BV-specific IgE antibodies, which can prime some individuals to exhibit anaphylaxis in response to a subsequent sting (Annila, 2000) . Mice can develop Th2 cell-mediated responses to BV when they are immunized with BV admixed with adjuvants such as Freund's complete adjuvant (Saelinger and Higginbotham, 1974) or aluminum hydroxide (Charavejasarn et al., 1975) . We tested whether injections of whole BV (without added adjuvants) also could induce type 2 immunity in mice (Figure 2A ; Figure S2A ).
We assessed responses to BV of primary T cells from draining inguinal lymph nodes (ILNs) from C57BL/6 or BALB/c mice 5 days after injection of either PBS or a sublethal dose of BV (i.e., one not resulting in the death of significant numbers of animals [p = 0.32 and p = 0.07 in Figures 1E and 1G Figures S2B and S2C ), IL-4, and IL-5, but no, or only low amounts of, the Th1 cell-associated cytokine interferon-g (IFN-g) ( Figure 2D ; Figure S2D ). Two weeks after injection of sublethal amounts of BV, we measured serum titers of BV-specific IgG 1 and total IgE, the two antibody isotypes associated with Th2 cell immune responses in mice. One, 2 or 3 s.c. injections of 200 mg BV induced significant elevation of BV-specific IgG 1 (p < 0.05, Figure 2E ) and total IgE (p < 0.05, Figure 2F ) antibodies in C57BL/6 mice. Mice on the Th2 cell-prone BALB/c background also developed marked increases in BV-specific IgG 1 (but without significant increases in total IgE) when immunized with BV ( Figures S2E  and S2F ). Together, our results show that mice can develop type 2 immune responses after exposure to amounts of BV that mimic actual bee stings.
Type 2 Immunity to Honeybee Venom Can Confer Increased Resistance to a High Dose of Venom Because both IgE and IgG 1 antibodies can orchestrate anaphylaxis and other allergic reactions in mice (Finkelman, 2007; Miyajima et al., 1997; Oettgen and Geha, 1999; Oettgen et al., 1994) , we speculated that a BV-induced Th2 cell response might prime mice to exhibit exacerbated reactions to subsequent BV challenge. In contrast, we found that 3 weeks after they had received a sublethal dose of BV, such mice exhibited markedly increased resistance to challenge with a potentially lethal dose of BV, i.e., 43 200 mg and 53 200 mg BV for C57BL/6 and BALB/c mice, respectively (which caused death in 90% or 70%, respectively, of 6-to 8-week-old naive WT animals [Figures 1E and 1G] ) (Figures 2G and 2H; Figures S2G and S2H) . For example, C57BL/6 mice that had been immunized with as little as 13 200 mg BV exhibited significantly less hypothermia (p < 0.001 at 1 and 6 hr, Figure 2G ) and markedly enhanced survival after potentially lethal BV challenge ( Figure 2H ). In BALB/c mice, even immunization with 13 100 mg BV induced enhanced protection (Figures S2G and S2H) .
Individual sera of protected mice obtained a week after BV challenge ( Figure 2A ; Figure S2A ) contained BV-specific IgE antibodies specific for BV ( Figure 2I ; Figure S2I ) and for the major BV allergen PLA 2 (data not shown), and such sera also markedly increased the ability of bone-marrow-derived cultured mast cells (BMCMCs) to degranulate in response to BV stimulation (Figure 2J ; Figure S2J ). Pretreatment of such pooled immune serum (collected from immunized and challenged mice) by heating (to ablate IgE function [Ishizaka et al., 1986; Prouvost-Danon et al., 1977; Strait et al., 2006] ) or by using an anti-mouse IgE antibody decreased its ability to sensitize BMCMCs to degranulate in response to BV (i.e., 100 ng/ml and 1,000 ng/ml; Figure 2K ; Figure S2K ), confirming that BV immunization induced production of functionally active BV-specific IgE antibodies. Both C57BL/6 and BALB/c mice injected with sublethal amounts of BV developed a Th2 cell immune response and exhibited increased resistance to challenge with a potentially lethal dose of BV. This finding is especially remarkable given that (1) BV consists of a variety of active toxins with different mechanisms of action (Habermann, 1972; Schmidt, 1995) and (2) type 2 immune responses against venoms (i.e., development of anti-venom IgG 1 and IgE antibodies) are classically thought to exacerbate the outcome of subsequent venom exposure (Annila, 2000; Biló et al., 2005; Charavejasarn et al., 1975; Jarisch et al., 1979; Reimers et al., 2000; Saelinger and Higginbotham, 1974; Wadee and Rabson, 1987 ( Ando et al., 1993; Finkelman, 2007; Miyajima et al., 1997) . We used passive immunization to evaluate whether the protective effect of BV immunization might be antibody mediated (Figure S3A) . Briefly, we immunized C57BL/6 mice with 23 200 mg BV (a sublethal dose [ Figure 1E ] that enhanced resistance of C57BL/6 mice to challenge with a high dose of BV [ Figures Transfer of BV serum (compared to transfer of PBS serum) conferred significantly increased resistance to high dose BV challenge, as assessed by body temperature (p < 0.01, Figure S3G) or survival (p < 0.001, Figure S3H ). Remarkably, passive immunization was as effective as active immunization (Figures S3G and S3H) . We concluded that soluble factors in the serum of BV-immunized mice are sufficient to increase host resistance to a potentially lethal dose of BV.
We next used two approaches in WT mice to assess the contribution of IgE antibodies to the protection conferred by immune serum ( Figure 3A) . First, we treated the BV serum with an anti-IgE antibody (i.e., ''anti-IgE BV serum'') before passive immunization. This approach is straightforward but risks inducing anaphylaxis due to formation of antibody immune-complexes that in turn activate effector cells. Indeed, 5 of the 20 mice that received anti-IgE BV serum developed severe hypothermia and died soon after the transfusion; the other 15 mice appeared normal and were used for the experiments shown in Figure 3 . We also passively immunized mice with heated BV serum ( Figure 3A) . Heating results in a loss of the ability of IgE to induce passive cutaneous anaphylaxis (Prouvost-Danon et al., 1977) , whereas the function of other antibody classes, including IgG 1 , is not affected (Strait et al., 2006) .
Notably, either heating (Figures 3B and 3C; orange triangles) or anti-IgE antibody treatment (Figures 3B and 3C ; inverted yellow triangles) essentially abolished the protective potential of BV serum (Figures 3B and 3C ; red diamonds) in mice challenged with 43 200 mg BV. These results support the conclusion that IgE antibodies substantially contribute to, or may fully account for, the immune serum's protective effect.
Honeybee-Venom-Immunized IgE-deficient Mice Do Not Develop Enhanced Resistance to the Venom In order to confirm the role of IgE antibodies in acquired host resistance against BV by using a genetic approach, we S4C ; Figure 4A ). Fourteen days after immunization with 13 100 mg BV, the serum of IgE-deficient animals contained specific IgG 1 antibodies at titers comparable to WT controls and, as expected, no detectable IgE ( Figures S4D and S4E ). As observed in prior experiments ( Figures S2G and S2H) , BV-immunized WT mice were significantly more resistant to challenge with 53 200 mg BV than were PBS mock-immunized mice (p < 0.01, Figures 4B and  4C) . In contrast, BV-immunized IgE-deficient mice were less resistant to high-dose BV challenge than were PBS mock-immunized IgEdeficient mice ( Figures 4B and 4C) . Notably, IgE-deficient mice that were passively immunized with untreated BALB/c BV serum (that had been confirmed to confer protection in BALB/c WT mice challenged with 53 200 mg BV [data not shown]) developed less hypothermia and exhibited lower mortality than mice that had received heated BV serum or PBS serum (Figures 4D-4F ). By contrast, transfer of dinitrophenyl (DNP)-specific monoclonal IgE antibody (that was functionally active in both IgE-deficient and WT mice [ Figures S4F to S4H] ), in amounts equivalent to the amounts of IgE transferred in BV serum, did not influence the resistance of recipient IgE-deficient mice to BV challenge ( Figures 4D-4F) .
Together with the results of our serum transfer experiments in WT C57BL/6 mice ( Figure 3 ) these findings support the conclusion that type 2 immune responses can enhance host resistance to honeybee venom by IgE-dependent mechanisms. reactions (Kawakami and Kitaura, 2005; Kinet, 1999; Rivera et al., 2008) . FcεRI contains one IgE-binding a chain, one b chain (that can function as a signal amplifier), and two signal-transducing g-chains (referred to as FcεRIa, FcεRIb, and FcεRIg, respectively) (Kinet, 1999; Rivera et al., 2008) ; FcεRIg also participates in the signaling of the IgG receptors FcgRI, FcgRIII, and FcgRIV (Bruhns, 2012; Kinet, 1999) . To elucidate the function of antibodies in host defense against BV, we used a genetic approach targeting cellmediated effects of IgG and IgE. First, we actively immunized mice lacking FcεRIg (C57BL/6-Fcer1g
) and C57BL/6 WT controls with 23 200 mg BV (a sublethal dose [ Figure 1E ] that enhanced resistance of C57BL/6 mice to challenge with a high dose of BV [Figures 2G and 2H] ) or injected them with PBS ( Figure S5A ; Figure 5A ). Naive Fcer1g À/À and WT animals exhibited similar acute systemic innate responses to initial BV injection ( Figures S5B and S5C ) and elevated serum levels of BVspecific IgG 1 and total IgE 2 weeks later ( Figures S5D and S5E ).
However, in contrast to WT mice, BV immunization did not protect Fcer1g À/À mice against challenge with a potentially lethal dose of BV ( Figures 5B and 5C ). These results demonstrate the importance of IgE and/or IgG-Fc-receptor signaling via the FcεRI g-chain for the protective effect of this venom-specific type 2 immune response. We then assessed whether BV immunization could enhance resistance to high dose BV challenge in BALB/c mice lacking only the IgE-binding FcεRIa chain (BALB/c-Fcer1a Figure 5A) (Galli and Tsai, 2012; Kinet, 1999; Oettgen and Geha, 1999; Rivera et al., 2008) , and previous reports by our lab (Akahoshi et al., 2011; Metz et al., 2006) and others (Schneider et al., 2007) indicate that MCs importantly contribute to the innate resistance to certain venoms (including BV [ (Metz et al., 2006) ]) and venom components (Akahoshi et al., 2011; Metz et al., 2006; Schneider et al., 2007) . We therefore speculated that MCs may also play an important role in acquired resistance to BV. Consistent with a previous report (Higginbotham and Karnella, 1971 ) and our in vitro experiments ( Figure 2K ; Figure S2K ), BV injection induced extensive MC degranulation at injection sites in both naive mice ( Figure 6A ) and mice injected 3 weeks earlier either with PBS or BV (Figure 6B) . Consistent with our previous findings (Metz et al., 2006) , MC-deficient C57BL/6-Kit W-sh/W-sh mice (whose MC deficiency is caused by a mutation affecting expression of Kit, the receptor for the MC survival and maturation factor stem cell factor) and C57BL/6-Cpa3-Cre + ;Mcl-1 fl/fl mice (whose marked MC deficiency and decreased numbers of basophils are not due to c-kit mutations [Lilla et al., 2011] (Theakston et al., 2003) . Together with the Indian cobra (Naja naja), the krait (Bungarus caerulaeus), and the saw scaled viper (Echis carinatus), the Russell's viper (Daboia russelii) composes the group of snakes referred to as the ''Big Four,'' which accounts for the majority of snake-bite-related deaths in India (Simpson and Norris, 2007 ). Russell's viper venom (RVV) is a complex mixture of growth factors and enzymes with procoagulant and neurotoxic activities (Risch et al., 2009) .
We defined sublethal and potentially lethal doses of RVV in C57BL/6 and BALB/c mice by using 2 s.c. injections in the back (mimicking a snake bite) containing 5-50 mg of RVV per each 50 ml injection (Figures S1A to S1C). Five and 12.5 mg of RVV per injection (i.e., 10 mg and 25 mg of total RVV, respectively), which did not cause death in a substantial number of C57BL/6 animals, were chosen as the immunizing doses (Figures S1D to S1G). Like with BV, immunization with RVV induced a type 2 immune response characterized by the development of RVV-specific T cells with a Th2 cell profile (Figures 7A-7C; Figures S6A to S6C) , as well as increased serum levels of RVVspecific IgG 1 ( Figure 7D ; Figure S6D ) and total IgE ( Figure 7E ; Figure S6E ). Three weeks after immunization, the mice were challenged with a potentially lethal dose of RVV (i.e., 23 37.5 mg RVV, which caused death in 100% of 6-to 8-week-old naive WT animals [ Figures S1E and S1G] ). Compared to PBS-injected mice, C57BL/6 and BALB/c mice that were immunized with 23 12.5 mg RVV exhibited less hypothermia ( Figure 7F; Figure S6F ) and markedly improved survival ( Figure 7G ; Figure S6G ). When we tested mice a week after RVV challenge, we detected functionally active RVV-specific IgE antibodies in the serum of the protected mice (Figures 7H-7J; Figures S6H-S6J ). These results show that IgE-associated type 2 immune responses induced by a reptile venom, i.e., Russell's viper venom, also can enhance resistance of the host to challenge with a high dose of venom.
DISCUSSION
We found that injecting mice with whole honeybee venom or Russell's viper venom can induce the differentiation of BV-or RVV-specific Th2 cells and the production of venom-specific IgG 1 and IgE antibodies. This was true in mice with genetic biases to develop either type 1 (C57BL/6) or type 2 (BALB/c) immune responses, suggesting that BV and RVV have strong intrinsic abilities to induce a Th2 cell-mediated immune response in mice. Notably, these BV-or RVV-induced IgE-associated type 2 immune responses enhanced host resistance to the toxicity of that venom. To our knowledge, our findings represent the first experimental evidence in support of Profet's ''toxin hypothesis.'' Profet hypothesized that one key beneficial function of acquired immunological responses known as ''allergic responses,'' which in some clinical settings contribute to disease, is to protect the host against venoms and other environmental toxins (Palm et al., 2012; Profet, 1991) .
We previously reported that MCs can reduce the toxicity of certain arthropod (including BV) and reptile venoms in mice (Akahoshi et al., 2011; Metz et al., 2006) . This MC-related enhanced innate resistance to venom toxicity depends at least in part on compounds released by activated MCs, such as proteases (including carboxypeptidase A3 and the chymase mMCP-4), which can degrade and neutralize certain venom components (Akahoshi et al., 2011; Metz et al., 2006; Schneider et al., 2007) . It is tempting to speculate that the occurrence of large numbers of MCs in the skin (a frequent site of envenomation) and around blood vessels (representing key ''access points'' that can facilitate the systemic distribution of venom components initially deposited locally at the site of stings or bites, thereby increasing their systemic toxicity) in part reflects evolutionary pressure to position MCs at sites where they can rapidly respond to venoms and thereby help to limit venom-induced pathology. Our data, which need extension by future studies, suggest that MCs can contribute not only to innate resistance but also to IgErelated acquired resistance to BV. Moreover, we showed that venom-specific IgE antibodies permitted MCs to be activated by lower amounts of venom than are required to activate MCs via antibody-independent innate mechanisms. It therefore seems reasonable to propose that the release of proteases that can degrade venom components (Akahoshi et al., 2011; Schneider et al., 2007) , and perhaps the secretion of other MC mediators such as heparin (Higginbotham and Karnella, 1971) , by MCs activated via venom-specific IgE can contribute to the acquired, IgE-associated enhanced resistance to bee venom.
It will be interesting to see how many additional examples of ''protective Th2 cell responses'' to toxins or other noxious substances will be identified. It also will be important to try to understand why some conditions of venom immunization and challenge result in venom-directed, IgE-associated Th2 cell responses that enhance host resistance to that venom, whereas others prime certain unfortunate individuals to exhibit serious and potentially fatal allergic responses, i.e., anaphylaxis, upon subsequent venom exposure (Annila, 2000; Biló et al., 2005; Reimers et al., 2000; Wadee and Rabson, 1987) . In considering this question, it should be noted that some people who develop Th2 cell responses to BV do not exhibit anaphylactic reactivity despite having venom-specific IgE antibodies (Antonicelli et al., 2002) . Also, there is abundant evidence that Th2 cell-mediated responses are subject to immune regulation, which can diminish pathology related to IgE-dependent reactivity to the inducing antigen, including BV (Meiler et al., 2008; Mü ller, 2005; Ozdemir et al., 2011) . These findings, taken together with those reported herein, raise the possibility that anaphylaxis represents only the most extreme and maladaptive end of a spectrum of acquired Th2 cell-mediated immunity to venom and that includes, at the other end of the spectrum, appropriately regulated Th2 cell immune responses that can enhance resistance to such venoms. It therefore will be of interest to assess the extent that genetic and environmental factors, as well as differences in the conditions, timing, and type of exposure to venoms or other potentially toxic antigens, can determine whether the Th2 cellmediated responses induced by such antigens confer net benefit or harm.
Although these and other questions raised by our findings remain to be answered, our experiments demonstrate that Th2 cell-mediated immune responses and the production of IgE antibodies, in addition to contributing to host defense against certain parasites, can confer a survival advantage in animals exposed to venoms.
EXPERIMENTAL PROCEDURES Mice
All animal care and experiments were carried out in accord with current National Institutes of Health guidelines and the approval of the Stanford University Institutional Animal Care and Use Committee. Six to 8-week-old female C57BL/6J or BALB/cJ mice were used in experiments involving solely WT mice. Transgenic mouse strains were bred and housed with the respective control mice in the local animal facilities. Transgenic C57BL/6-Fcer1g À/À mice were purchased from Taconic. BALB/c-Fcer1a
À/À mice were originally obtained from Jean-Pierre Kinet (Harvard Medical School). C57BL/6-Fcer1a À/À mice were purchased from Jackson Laboratories. IgE-deficient BALB/c (Igh-7 À/À ) mice were generated as described (Oettgen et al., 1994) . Mast-cell deficient C57BL/6-Kit W-sh/W-sh mice were extensively backcrossed onto the C57BL/6J background (Piliponsky et al., 2010) and MC-and basophil-deficient C57BL/6-Cpa3-Cre; Mcl-1 fl/fl mice (Lilla et al., 2011) were generated as described. Age-matched male and female transgenic mice were used for experiments (with comparable gender distribution within the groups). See Supplemental Experimental Procedures for additional information.
Reagents
Honeybee venom was from ALK Abello Source Materials; Russell's viper venom was from Sigma. Additional information on venoms and other reagents are in the Supplemental Experimental Procedures. Figure 2A outlines the active immunization protocol (see Supplemental Experimental Procedures for details). Briefly, 6-to 8-week-old WT or transgenic mice were shaved at injection sites 24 hr before injections and always received, in the morning, one or several s.c. injections of PBS alone or containing 100 mg or 200 mg BV. For experiments with RVV, mice were immunized by two s.c. injections of PBS alone or PBS containing 5-50 mg of RVV per injection. On day 21, mice on the C57BL/6 or BALB/c background were challenged s.c. (without anesthesia) by four or five injections of 200 mg BV or with 2 s.c. injections of 37.5 mg RVV (in back skin). Body temperature was measured with a rectal thermometer immediately before and at various times after challenge.
Venom Injections and Active Immunization

Measurement of Serum Antibodies
Serum antibody levels were measured with ELISA (see Supplemental Experimental Procedures for details).
BMCMC Generation and Analysis of Serum for Functional IgE
See Supplemental Experimental Procedures.
Passive Immunization -Serum Preparation and Transfer Figure S2A outlines the passive immunization protocol (see Supplemental Experimental Procedures for details). Briefly, for experiments in Figure 3 , 6-to 8-week-old female C57BL/6J ''donor'' mice were immunized by 2 s.c. injections of 200 mg BV or with PBS alone; 3 weeks later, serum antibody levels were measured. Aliquots of pooled serum derived from ''donor'' mice, which had been injected with either PBS or BV are referred to as PBS serum or BV serum, respectively. BV serum was either supplemented with a rat anti-mouse IgE antibody (Amiri et al., 1994; Haak-Frendscho et al., 1998) for at least 30 min at room temperature (anti-IgE BV serum) or was supplemented with a rat isotype control antibody and left untreated (untreated BV serum) or was heated 60 min at 56 C (heated BV serum). PBS serum also was supplemented with the rat isotype control antibody at the time of the transfer. Aliquots of these modified sera were transfused i.v. into 10-to 11-week-old female C57BL/6 ''recipient'' mice. The next day, ''recipient'' mice were challenged with 4 s.c. injections (33 back, 13 belly) of 200 mg BV. We measured body temperature at indicated times and assessed survival over 1 week.
Flow Cytometry
Statistical Analysis
Statistical tests were performed with the software GraphPad PRISM 6. Twotailed Student's t test (unpaired), two-way ANOVA, chi-square, or MantelCox tests were performed as noted in the respective figure legends. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. = not significant (p > 0.05). 
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